-+ 0.00%
-+ 0.00%
-+ 0.00%

Heyu-B announced that Shanghai Heyu Biomedical Technology Co., Ltd., a subsidiary of the company, announced that its highly selective small molecule FGFR2/3 inhibitor ABSK061 has successfully completed the first patient administration in a phase II clinical trial for children with achondroplasia aged 3-12.

Zhitongcaijing·12/16/2025 00:41:02
Listen to the news
Heyu-B announced that Shanghai Heyu Biomedical Technology Co., Ltd., a subsidiary of the company, announced that its highly selective small molecule FGFR2/3 inhibitor ABSK061 has successfully completed the first patient administration in a phase II clinical trial for children with achondroplasia aged 3-12.